Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02836093 |
Recruitment Status :
Active, not recruiting
First Posted : July 18, 2016
Last Update Posted : January 29, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Breast Cancer Fatigue | Behavioral: FACIT-Fatigue 52-point questionnaire |
Study Type : | Observational |
Actual Enrollment : | 45 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Pilot Study for Assessment of Exercise Capacity in Breast Cancer Patients With Radiotherapy-Related Fatigue |
Actual Study Start Date : | July 2016 |
Estimated Primary Completion Date : | July 2021 |
Estimated Study Completion Date : | July 2021 |

Group/Cohort | Intervention/treatment |
---|---|
evaluations/assessments |
Behavioral: FACIT-Fatigue 52-point questionnaire |
- fatigue measurement using the 13-item FACIT-fatigue scale [ Time Frame: 1 year ]Fatigue will be assessed using the 13-item FACIT-fatigue scale for the assessment of fatigue in cancer patients.24 The FACIT-Fatigue is a validated questionnaire that was originally developed for the precise evaluation of fatigue levels in cancer patients with anemia. It consists of 13 questions using a 5 point scale (0=not at all; 1 = a little bit, 2 = somewhat, 3 = quite a bit and 4 = very much). It has been used frequently in the clinical trial setting (please see appendix 1). Responses to each question are added with equal weight to obtain a total score. The range of possible scores is 0-52, with 0 corresponding to the highest level of fatigue and 52 corresponding to the lowest level of fatigue.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Female
- ECOG performance status 0 or 1
- Medical clearance from attending radiation oncologist or medical oncologist to undergo a symptom-limited CPET
- Currently undergoing intact breast radiotherapy for early stage breast cancer (including TisN0, T1N0, T2N0) or has completed intact breast RT in the last 3 months.
- Receiving or received a prescribed dose of 4240 cGy in 16 fractions to the whole breast without treatment directed at nodal basins. Patients may also be receiving or have received a boost to the lumpectomy bed at the discretion of the treating physician.
- Subjects may be treated in the supine or prone position at the discretion of the treating physician.
- Subjects may be treated with or without a deep inspiratory breath hold technique at the discretion of the treating physician.
- Identified by the treating radiation oncologist as having significant treatment-related fatigue or minimal treatment-related fatigue and not simply baseline fatigue. A score of "0" on the RTOG fatigue scale will be considered minimal fatigue, while a score of "2" or greater will be considered significant fatigue (moderate fatigue causing difficulty performing some ADLs).
Exclusion Criteria:
- Currently undergoing post-mastectomy radiation
- Has received chemotherapy previously or has a plan to receive chemotherapy during the timeframe of study assessment.
-
Any of the following absolute contraindications to CPET, as per American Thoracic Society (ATS) recommendations
- Acute myocardial infarction (within 3-5 days of any planned study procedures)
- Unstable angina
- Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
- Recurrent syncope
- Active endocarditis
- Acute myocarditis or pericarditis
- Symptomatic severe aortic stenosis
- Uncontrolled heart failure
- Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures
- Thrombosis of lower extremities
- Suspected dissecting aneurysm
- Uncontrolled asthma
- Pulmonary edema
- Room air desaturation at rest ≤ 85%
- Respiratory failure
- Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)
- Mental impairment leading to inability to cooperate

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02836093
United States, New Jersey | |
Memoral Sloan Kettering Basking Ridge (Consent only) | |
Basking Ridge, New Jersey, United States, 07920 | |
Memorial Sloan Kettering Monmouth (Consent only) | |
Middletown, New Jersey, United States, 07748 | |
Memorial Sloan Kettering Bergen (Consent only) | |
Montvale, New Jersey, United States, 07645 | |
United States, New York | |
Memorial Sloan Kettering Commack (Consent only) | |
Commack, New York, United States, 11725 | |
Memorial Sloan Kettering Westchester (Consent only) | |
Harrison, New York, United States, 10604 | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 | |
Memorial Sloan Kettering Rockville Centre (Consent only) | |
Rockville Centre, New York, United States, 11570 |
Principal Investigator: | Beryl McCormick, MD | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT02836093 |
Other Study ID Numbers: |
16-941 |
First Posted: | July 18, 2016 Key Record Dates |
Last Update Posted: | January 29, 2020 |
Last Verified: | January 2020 |
Exercise Radiation Treatment 16-941 |
Breast Neoplasms Fatigue Neoplasms by Site |
Neoplasms Breast Diseases Skin Diseases |